Back to search results

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

Abroad (travel likely)RecruitingPHASE1

Conditions

COVID-19

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The Hope Clinic of Emory University, Decatur, Georgia, United States

    Contact: Study coordinator (Site Recruitment Contact) · gosinsk@emory.edu · 4047121371

  • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

    Contact: Study coordinator (Site Recruitment Contact) · clintrial@som.umaryland.edu · 4107068800

  • Brigham and Women's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Site Recruitment Contact) · vaccines@partners.org · 6175257327

  • Saint Louis University Center for Vaccine Development, St Louis, Missouri, United States

    Contact: Study coordinator (Site Recruitment Contact) · vaccine@health.slu.edu · 3149776333

  • Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit, St Louis, Missouri, United States

  • University of Texas Medical Branch, Galveston, Texas, United States

    Contact: Study coordinator (Site Recruitment Contact) · roacox@UTMB.EDU · 4097725278
View source on ClinicalTrials.gov(opens in a new tab)